Sage, Biogen
Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...
Zacks.com on MSN1d
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other UpdatesIt was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...
Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...
Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...
As I ran from interview to interview across San Francisco, I was consistently warmed by the stories I was told by biotech and ...
Today's sure has SAGE on track for its largest single-day percentage gain since January 2019. Though further removed from ...
Truist keeps a Hold rating on Sage Therapeutics (SAGE) after Zurzurvae’s commercial partner Biogen (BIIB) disclosed an unsolicited proposal to acquire the company for $7.22 per share.
The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...
RBC Capital Mkts has recently raised SAGE Therapeutics Inc (SAGE) stock to Sector Perform rating, as announced on November 21, 2024, according to Finviz. Earlier, on October 10, 2024, Raymond James ...
Intellia Therapeutics announced its strategic priorities and key anticipated milestones for 2025. However, investors were ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback